NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 08 04:00PM ET
2.71
Dollar change
-0.02
Percentage change
-0.73
%
IndexRUT P/E- EPS (ttm)-1.17 Insider Own12.93% Shs Outstand109.71M Perf Week12.92%
Market Cap297.33M Forward P/E- EPS next Y-1.45 Insider Trans-0.27% Shs Float95.53M Perf Month6.27%
Enterprise Value61.94M PEG- EPS next Q-0.37 Inst Own87.98% Short Float10.60% Perf Quarter60.36%
Income-167.38M P/S- EPS this Y-45.07% Inst Trans-5.92% Short Ratio6.47 Perf Half Y-50.73%
Sales0.00M P/B1.22 EPS next Y1.20% ROA-55.14% Short Interest10.12M Perf YTD-47.17%
Book/sh2.22 P/C1.13 EPS next 5Y2.82% ROE-66.13% 52W High7.85 -65.48% Perf Year-43.48%
Cash/sh2.40 P/FCF- EPS past 3/5Y33.38% -0.09% ROIC-62.11% 52W Low1.28 110.89% Perf 3Y-28.12%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility10.96% 8.05% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM19.76% Oper. Margin- ATR (14)0.20 Perf 10Y-
Dividend Ex-Date- Quick Ratio7.99 Sales Y/Y TTM- Profit Margin- RSI (14)61.03 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio7.99 EPS Q/Q-78.85% SMA207.24% Beta1.29 Target Price11.60
Payout- Debt/Eq0.12 Sales Q/Q- SMA5023.19% Rel Volume0.80 Prev Close2.73
Employees100 LT Debt/Eq0.11 EarningsMay 12 BMO SMA200-31.36% Avg Volume1.56M Price2.71
IPOJul 24, 2020 Option/ShortYes / Yes EPS/Sales Surpr.-24.75% - Trades Volume1,256,784 Change-0.73%
Date Action Analyst Rating Change Price Target Change
Mar-01-24Upgrade JP Morgan Neutral → Overweight $11
Dec-21-23Upgrade BofA Securities Neutral → Buy $4 → $6
Oct-30-23Initiated Wells Fargo Overweight $11
May-26-23Downgrade BofA Securities Buy → Neutral $8 → $3
May-25-23Downgrade JP Morgan Overweight → Neutral $19 → $9
Sep-16-22Initiated Jefferies Buy $12
Sep-09-22Initiated BTIG Research Buy $15
Nov-30-21Initiated H.C. Wainwright Buy $40
Sep-23-21Initiated Cantor Fitzgerald Overweight $40
Jan-26-21Initiated Needham Buy $37
Jun-18-25 04:05PM
May-29-25 04:05PM
May-19-25 04:05PM
04:05PM
May-16-25 04:05PM
08:00AM Loading…
May-12-25 08:00AM
May-09-25 05:00PM
05:00PM
May-07-25 08:00AM
Apr-16-25 04:05PM
Apr-15-25 07:12AM
Apr-10-25 09:24AM
Apr-09-25 03:20PM
Apr-08-25 04:05PM
04:05PM
06:18PM Loading…
Apr-03-25 06:18PM
06:18PM
Mar-17-25 04:05PM
Mar-16-25 06:05AM
Mar-03-25 08:00AM
Feb-26-25 04:05PM
Feb-18-25 08:00AM
Feb-13-25 08:30AM
Jan-13-25 08:00AM
Jan-10-25 08:00AM
Jan-07-25 08:00AM
Dec-16-24 04:05PM
07:30AM
Dec-05-24 08:00AM
Nov-19-24 03:00AM
04:59PM Loading…
Nov-15-24 04:59PM
Nov-14-24 08:00AM
Nov-13-24 04:05PM
Oct-21-24 08:00PM
Oct-16-24 08:00AM
Oct-15-24 08:00AM
Sep-16-24 08:00AM
Sep-09-24 08:00AM
Sep-03-24 08:00AM
Aug-29-24 08:00AM
Aug-16-24 04:05PM
Aug-12-24 08:00AM
Aug-05-24 08:00AM
Jul-16-24 04:05PM
Jul-11-24 06:09PM
Jun-29-24 08:48PM
Jun-28-24 09:40AM
Jun-27-24 09:55AM
Jun-25-24 05:00PM
05:00PM
Jun-24-24 06:35AM
Jun-18-24 08:00AM
Jun-17-24 04:05PM
Jun-07-24 09:40AM
Jun-05-24 11:04PM
10:57AM
09:55AM
04:45AM
Jun-04-24 05:06PM
12:06PM
08:46AM
07:28AM
07:00AM
07:00AM
Jun-03-24 04:30PM
May-20-24 09:35AM
May-16-24 04:05PM
May-13-24 02:53PM
08:00AM
May-09-24 08:00AM
May-07-24 12:30PM
May-01-24 10:15AM
08:00AM
Apr-25-24 09:35AM
Apr-17-24 09:40AM
Apr-16-24 04:05PM
09:00AM
Apr-14-24 12:52PM
Apr-10-24 06:15PM
Apr-03-24 08:00AM
Apr-01-24 12:00PM
09:55AM
Mar-28-24 05:31AM
Mar-26-24 08:53PM
04:05PM
Mar-18-24 04:05PM
Mar-14-24 08:40AM
Mar-12-24 02:51PM
Feb-27-24 08:00AM
Feb-21-24 08:00AM
Feb-20-24 04:05PM
Feb-13-24 01:10PM
Jan-18-24 09:40AM
Jan-17-24 11:06AM
Jan-07-24 08:00PM
Dec-27-23 06:30AM
Dec-20-23 05:27PM
05:10PM
05:08PM
Dec-18-23 04:01PM
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Carson William H.DirectorJun 30 '25Buy2.464,11510,12329,715Jul 01 04:55 PM
Dananberg JamieCHIEF MEDICAL OFFICERFeb 18 '25Sale2.965,52116,34233,479Feb 20 04:54 PM
ARTIS DEAN RICHARDEVP & CHIEF SCIENTIFIC OFFICERFeb 18 '25Sale2.975,51516,38083,814Feb 20 04:52 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERFeb 18 '25Sale2.918,34524,28461,237Feb 20 04:51 PM
Overdorf MichaelEVP & CHIEF BUSINESS OFFICERFeb 18 '25Sale2.956,61819,52386,579Feb 20 04:49 PM
Lew JenniferEVP & CHIEF FINANCIAL OFFICERFeb 18 '25Sale2.926,91220,18377,770Feb 20 04:48 PM
Love DouglasPRESIDENT AND CEOFeb 13 '25Sale2.955,02114,812351,554Feb 18 04:30 PM
Lew JenniferEVP & CHIEF FINANCIAL OFFICERFeb 13 '25Sale2.981,7865,32284,682Feb 18 04:30 PM
Overdorf MichaelEVP & CHIEF BUSINESS OFFICERFeb 13 '25Sale2.991,4254,26193,197Feb 18 04:30 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERFeb 13 '25Sale2.991,7835,33169,582Feb 18 04:30 PM
Yednock TedOfficerFeb 18 '25Proposed Sale2.918,34524,321Feb 18 03:21 PM
Lew JenniferOfficerFeb 18 '25Proposed Sale2.928,33824,319Feb 18 03:15 PM
ARTIS DEAN RICHARDOfficerFeb 18 '25Proposed Sale2.975,51516,359Feb 18 03:15 PM
Dananberg JamieOfficerFeb 18 '25Proposed Sale2.965,52116,359Feb 18 03:13 PM
Overdorf MichaelOfficerFeb 18 '25Proposed Sale2.956,61819,514Feb 18 03:11 PM
Yednock TedOfficerFeb 13 '25Proposed Sale2.981,7835,316Feb 13 03:18 PM
Love DouglasOfficerFeb 13 '25Proposed Sale2.955,02114,799Feb 13 03:13 PM
Lew JenniferOfficerFeb 13 '25Proposed Sale2.981,7865,314Feb 13 03:12 PM
Overdorf MichaelOfficerFeb 13 '25Proposed Sale2.991,4254,265Feb 13 03:06 PM
Love DouglasPRESIDENT AND CEOJan 06 '25Option Exercise1.4137,99453,556356,575Jan 08 05:58 PM
Carson William H.DirectorDec 02 '24Buy5.333,20017,05625,600Dec 04 06:12 PM
Love DouglasPRESIDENT AND CEOOct 30 '24Option Exercise1.85114,449211,742310,570Nov 01 04:15 PM
Yednock TedEVP & CHIEF INNOVATION OFFICEROct 15 '24Option Exercise1.855,40810,00576,773Oct 17 05:09 PM
Yednock TedEVP & CHIEF INNOVATION OFFICEROct 15 '24Sale7.415,40840,07371,365Oct 17 05:09 PM
Yednock TedOfficerOct 15 '24Proposed Sale7.415,40840,073Oct 15 02:03 PM
Carson William H.DirectorOct 01 '24Buy5.973,20019,10422,400Oct 02 04:15 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERSep 19 '24Sale7.104,50031,9500Sep 20 04:30 PM
Yednock TedOfficerSep 19 '24Proposed Sale7.104,50031,950Sep 19 12:32 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERSep 12 '24Sale6.165,50033,8804,500Sep 16 04:30 PM
Yednock TedOfficerSep 12 '24Proposed Sale6.165,50033,880Sep 12 10:24 AM
Yednock TedEVP & CHIEF INNOVATION OFFICERSep 05 '24Sale5.645,50031,02010,000Sep 06 04:30 PM
Yednock TedOfficerSep 05 '24Proposed Sale5.645,50031,020Sep 05 10:15 AM
Carson William H.DirectorSep 03 '24Buy5.483,20017,53619,200Sep 04 04:34 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERAug 29 '24Sale5.955,50032,72515,500Aug 30 06:00 PM
Yednock TedOfficerAug 29 '24Proposed Sale5.955,50032,725Aug 29 02:08 PM
Carson William H.DirectorAug 01 '24Buy6.243,20019,96816,000Aug 05 07:53 PM
Overdorf MichaelEVP & CHIEF BUSINESS OFFICERJul 15 '24Sale6.027844,72094,622Jul 17 04:49 PM
Lew JenniferEVP & CHIEF FINANCIAL OFFICERJul 15 '24Sale6.031,1046,65786,468Jul 17 04:48 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERJul 15 '24Sale6.021,1066,65871,365Jul 17 04:46 PM
Last Close
Jul 08 04:00PM ET
0.7102
Dollar change
+0.0109
Percentage change
1.56
%
XLO Xilio Therapeutics Inc daily Stock Chart
Index- P/E- EPS (ttm)-0.84 Insider Own68.53% Shs Outstand51.78M Perf Week4.46%
Market Cap36.77M Forward P/E- EPS next Y-0.80 Insider Trans0.30% Shs Float16.30M Perf Month4.70%
Enterprise Value-44.44M PEG- EPS next Q-0.10 Inst Own16.12% Short Float16.10% Perf Quarter4.49%
Income-54.30M P/S3.97 EPS this Y44.05% Inst Trans-31.00% Short Ratio2.02 Perf Half Y-33.63%
Sales9.27M P/B3.44 EPS next Y-31.76% ROA-58.29% Short Interest2.62M Perf YTD-25.63%
Book/sh0.21 P/C0.41 EPS next 5Y-4.53% ROE-297.84% 52W High1.70 -58.22% Perf Year-17.71%
Cash/sh1.72 P/FCF1.75 EPS past 3/5Y26.76% -11.55% ROIC-313.20% 52W Low0.62 14.55% Perf 3Y-75.68%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin80.74% Volatility3.88% 4.40% Perf 5Y-
Dividend TTM- EV/Sales-4.79 EPS Y/Y TTM67.24% Oper. Margin-614.16% ATR (14)0.04 Perf 10Y-
Dividend Ex-Date- Quick Ratio1.96 Sales Y/Y TTM- Profit Margin-585.54% RSI (14)49.57 Recom1.50
Dividend Gr. 3/5Y- - Current Ratio1.96 EPS Q/Q71.18% SMA203.83% Beta-0.12 Target Price4.00
Payout- Debt/Eq0.73 Sales Q/Q- SMA50-6.32% Rel Volume0.28 Prev Close0.70
Employees64 LT Debt/Eq0.62 EarningsMay 08 BMO SMA200-18.32% Avg Volume1.30M Price0.71
IPOOct 22, 2021 Option/ShortNo / Yes EPS/Sales Surpr.6.59% -34.09% Trades Volume370,770 Change1.56%
Date Action Analyst Rating Change Price Target Change
Dec-21-22Initiated Chardan Capital Markets Buy $7
Jan-10-22Initiated H.C. Wainwright Buy $36
Nov-16-21Initiated Raymond James Outperform $31
Nov-16-21Initiated Morgan Stanley Overweight $32
Nov-16-21Initiated Guggenheim Buy $40
Nov-16-21Initiated Cowen Outperform
Jul-02-25 04:30PM
Jun-10-25 04:30PM
Jun-05-25 06:38PM
Jun-03-25 04:30PM
Jun-02-25 08:46AM
06:11AM Loading…
06:11AM
May-31-25 08:00AM
May-08-25 07:30AM
May-02-25 04:30PM
Apr-23-25 04:30PM
Apr-04-25 04:30PM
Mar-11-25 08:45AM
07:30AM
Feb-24-25 04:30PM
Feb-13-25 04:17AM
10:44AM Loading…
Feb-12-25 10:44AM
07:35AM
07:33AM
Feb-03-25 04:30PM
Jan-22-25 09:00AM
Jan-21-25 05:05PM
Jan-17-25 04:30PM
Jan-10-25 05:00PM
Dec-19-24 07:30AM
Dec-16-24 07:30AM
Dec-09-24 09:55AM
Dec-03-24 04:30PM
Nov-07-24 09:15AM
09:05AM
Oct-30-24 09:01AM
09:05AM Loading…
Oct-04-24 09:05AM
Oct-02-24 04:15PM
Aug-28-24 04:01PM
Aug-08-24 07:30AM
Jun-13-24 04:05PM
May-29-24 06:05AM
May-14-24 01:54PM
07:30AM
Apr-16-24 09:14AM
Apr-01-24 10:53PM
04:05PM
Mar-28-24 11:10AM
07:05AM
07:00AM
06:45AM
Feb-28-24 04:01PM
Jan-31-24 04:01PM
Jan-08-24 07:30AM
Dec-07-23 07:30AM
Nov-09-23 04:01PM
Nov-03-23 12:00PM
Oct-31-23 09:15AM
Sep-27-23 05:02PM
Sep-05-23 08:30AM
07:30AM
Aug-18-23 04:27AM
Aug-14-23 07:30AM
Aug-03-23 04:05PM
May-25-23 05:01PM
May-09-23 07:30AM
Apr-03-23 04:05PM
Mar-02-23 04:05PM
Feb-27-23 07:30AM
Feb-16-23 07:30AM
Feb-02-23 07:30AM
Jan-26-23 05:30AM
Jan-25-23 09:45AM
Nov-23-22 07:30AM
Nov-09-22 07:30AM
Nov-04-22 07:30AM
Sep-22-22 04:05PM
Sep-15-22 04:05PM
Sep-06-22 04:05PM
Aug-11-22 09:41AM
Aug-09-22 07:30AM
Jun-16-22 07:30AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 07:30AM
Apr-07-22 06:30AM
Mar-01-22 06:30AM
Feb-28-22 06:30AM
Feb-07-22 05:38PM
Feb-03-22 06:30AM
Jan-25-22 10:27AM
Jan-20-22 07:30AM
Jan-06-22 07:30AM
Dec-02-21 07:30AM
Nov-12-21 07:00AM
Oct-27-21 07:45AM
Oct-26-21 04:05PM
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shannon James SamuelDirectorJun 16 '25Buy0.6945,00030,87045,000Jun 18 04:57 PM
Shannon James SamuelDirectorJun 17 '25Buy0.6925,00017,21570,000Jun 18 04:57 PM
Russo RenePRESIDENT AND CEOJun 16 '25Buy0.6836,28924,680281,172Jun 18 04:56 PM
Frankenfield Christopher JamesChief Financial OfficerJan 02 '25Sale0.986,9546,84112,421Jan 03 04:15 PM
Brennan Kevin M.SVP, FINANCE AND ACCOUNTINGJan 02 '25Sale0.981,8031,7743,197Jan 03 04:15 PM
GILEAD SCIENCES, INC.10% OwnerDec 18 '24Buy1.041,759,9781,830,3779,105,451Dec 19 04:19 PM